Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $5.07 and last traded at $5.03, with a volume of 3355595 shares traded. The stock had previously closed at $4.82.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on XERS shares. Craig Hallum boosted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Jefferies Financial Group restated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $5.92.

Xeris Biopharma Trading Up 5.6 %

The company’s fifty day simple moving average is $3.79 and its 200 day simple moving average is $3.37. The stock has a market capitalization of $848.21 million, a P/E ratio of -12.24 and a beta of 2.32.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC bought a new stake in Xeris Biopharma during the fourth quarter valued at approximately $34,000. R Squared Ltd bought a new position in shares of Xeris Biopharma in the 4th quarter worth $42,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma during the 3rd quarter valued at $44,000. Cibc World Markets Corp bought a new stake in shares of Xeris Biopharma during the 4th quarter worth $44,000. Finally, Raymond James Financial Inc. purchased a new position in Xeris Biopharma in the fourth quarter worth $45,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.